<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-148521</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effect of desferrioxamine and deteriprone on the 1, 25 (OH)2D3- stimulated osteocalcin secretion in osteoblast-like cells</dc:title>
<dc:description xml:lang="en">Desferrioxamine and deferiprone are both metal-chelating drugs often used in aluminum-overloaded dialysis patients. In these patients, desferrioxamine produces an improvement on bone mineralisation without a relevant decrease in bone aluminum. Thus, desferrioxamine might have a direct effect on bone cells. The aim of this study was to assess the effect of desferrioxamine and deferiprone on 1,25(OH)2D3-stimulated osteocalcin secretion in osteoblast-like cells. The study was carried out in MG-63 cell cultures. Cells were seeded at a density of 15,000 cel/cm2 and grown to confluence for 72 hours in DMEM supplemented with 10% FCS. The medium was then replaced by another medium containing 1% BSA, 10-9M 1,25(OH)2D3 and desferrioxamine 5, 10, 20, 40, 60, 80 &amp;#956;M or deferiprone 15, 30, 60, 120, 180, 240 &amp;#956;M. Tris-HCl at pH 7.4 was used as control. After 48 hours, supernatants were collected for the measurement of secreted osteocalcin. Desferrioxamine and deferiprone, at high doses (desferrioxamine: 60 &amp;#956;M, 80 &amp;#956;M; deferiprone: 180 &amp;#956;M, 240 &amp;#956;M), inhibited the 1,25(OH)2D3-induced osteocalcin secretion. On the contrary, at lower doses (desferrioxamine 5 &amp;#956;M; deferiprone 15 &amp;#956;M) stimulated the secretion. In summary, these results suggest that desferrioxamine and deferiprone exert a direct effect on bone cell metabolism that might be independent from their metalchelating properties (AU)</dc:description>
<dc:creator>González Suárez, I</dc:creator>
<dc:creator>Fernández Martín, JL</dc:creator>
<dc:creator>Cannata Andía, JB</dc:creator>
<dc:creator>Naves Díaz, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La desferrioxamina y la deferiprona son dos drogas quelantes de metales que se emplean en la sobrecarga alumínica de los pacientes en diálisis. Se ha descrito que la desferrioxamina mejora la mineralización ósea, sin descensos importantes de la concentración de aluminio en hueso. Esto sugiere un efecto directo de la desferrioxamina sobre las células óseas. El objetivo de este trabajo fue evaluar el efecto de desferrioxamina y deferiprona sobre células óseas de estirpe osteoblástica. El estudió se realizó en cultivos de células MG-63. Las células se sembraron a una densidad de 15.000 cel/cm2 y se llevaron a confluencia en un medio DMEM con 10% FCS. Tras 72 horas, se reemplazó el medio por el de ensayo: 1% BSA, 10-9M 1,25(OH)2D3 y desferrioxamina 5, 10, 20, 40, 60, 80 &amp;#956;M o deferiprona 15, 30, 60, 120, 180, 240 &amp;#956;M. Como control se utilizó Tris-HCl a pH 7,4. A las 48 horas se recogieron los sobrenadantes y se midió la osteocalcina secretada. La desferrioxamina y la deferiprona inhibieron la secreción de osteocalcina inducida por vitamina D a concentraciones elevadas (desferrioxamina: 60 &amp;#956;M, 80 &amp;#956;M; deferiprona: 180 &amp;#956;M, 240 &amp;#956;M) mientras que la estimularon a bajas concentraciones (desferrioxamina 5 &amp;#956;M; deferiprona 15 &amp;#956;M). Estos resultados sugieren que tanto la desferrioxamina como la deferiprona son capaces de ejercer un efecto directo sobre el metabolismo del hueso independientemente de su capacidad quelante de metales (AU)</dc:description>
<dc:source>Nefrologia;23(supl.2): 27-31, 2003. graf</dc:source>
<dc:identifier>ibc-148521</dc:identifier>
<dc:title xml:lang="es">Efecto de la desferrioxamina y de ladeferiprona sobre la secreción de osteocalcina en células tipo osteoblasto</dc:title>
<dc:subject>^d24820^s22063</dc:subject>
<dc:subject>^d13017^s22021</dc:subject>
<dc:subject>^d4365</dc:subject>
<dc:subject>^d2151^s22078</dc:subject>
<dc:subject>^d23045^s22063</dc:subject>
<dc:subject>^d536</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22379</dc:subject>
<dc:subject>^d24403^s22053</dc:subject>
<dc:subject>^d3491^s22078</dc:subject>
<dc:subject>^d10184^s22021</dc:subject>
<dc:subject>^d10184^s22063</dc:subject>
<dc:subject>^d841</dc:subject>
<dc:subject>^d12165^s22078</dc:subject>
<dc:subject>^d12165^s22000</dc:subject>
<dc:subject>^d2659^s22078</dc:subject>
<dc:subject>^d3689^s22000</dc:subject>
<dc:subject>^d23045^s22021</dc:subject>
<dc:subject>^d3689^s22078</dc:subject>
<dc:subject>^d2659^s22000</dc:subject>
<dc:subject>^d1884^s22053</dc:subject>
<dc:subject>^d2151^s22006</dc:subject>
<dc:type>article</dc:type>
<dc:date>200300</dc:date>
</metadata>
</record>
</ibecs-document>
